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Abstract
Background: A point-of-care test (POCT) for sexually transmitted infections (STIs), which offers immediate diagnosis
resulting in patients receiving diagnosis and treatment in a single visit, has the ability to address some of the STI control
needs. However, needs assessment from STI experts and end users about currently available STI POCTs and their future new
development has not been evaluated since World Health Organization Sexually Transmitted Diseases Diagnostics Initiative
was formed over 15 years ago. Therefore, our objective was to explore the perceptions of the ideal types of STI POCT for use
in health care settings.
Methodology/Principal Findings: A qualitative study, encompassing eight focus groups, was conducted from March 2008
through April 2009. Participants included 6 STD clinic directors, 63 clinicians, and 7 public health/laboratory/epidemiology
professionals in the STI field. Discussion topics included currently available POCT, perceived barriers to using POCT in clinics,
priority STI for the development of new POCT, and characteristics of the ideal POCT. All discussions were recorded and
transcribed verbatim. Themes raised as barriers for current POCT included complexity, long time frames of the so-called
‘‘rapid’’ test, multiple time-driven steps, requiring laboratory technician, difficulty in reading result, interruption of workflow,
unreliability, and invasiveness. Chlamydia trachomatis was identified as the priority organism for development of a new STI
POCT. Themes indicated for the ideal POCT included rapid turnaround (up to 20 minutes), ease of use, non-invasive,
accurate (preferred sensitivity and specificity in the range of high 90s), Clinical Laboratory Improvement Amendments
(CLIA)-waived, user-friendly (for both patients and staff), compact, durable, and sturdy.
Conclusions/Significance: Focus group discussions with STI experts and professionals highlighted chlamydia as the top
priority pathogen for POCT development, and identified the qualities of new POCT for STIs. Participants endorsed ease of
use, rapid turnaround and high accuracy as essential characteristics of an ideal POCT.
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Introduction
Sexually transmitted infections (STIs), caused by more than 30
different sexually transmissible microorganisms, comprise the
leading group of reportable diseases in the United States each
year with an annual estimate of more than 19 million new cases
[1] and 9.3–15.5 billion dollars in costs [2,3]. Current diagnostic
testing algorithms result in a turn-around time of 2–14 days before
laboratory test results are available to clinical providers and
patients. This has contributed to low rates of patient return for test
results [4,5], reinfection of the presenting patient, and ongoing
transmission of infection in the patient’s partner(s). All of which
exacerbate an ongoing public health problem [6,7]. Due to the
sexual nature of the transmission mode, STIs carry strong social
and cultural stigma and, consequently, many cases remain
undiagnosed or something to that effect. Stigma is thought to be
one of most important factors for inadequate access to effective
STI diagnosis and treatment [3,8,9,10]. Stigma also disparately
affect women, minorities, adolescents, marginalized and disen-
franchised populations, the same vulnerable subgroup populations
that STIs greatly impact and who often have little access to health
care [11]. Therefore, an accurate STI diagnostic with rapid turn-
around time can provide clinicians with specific test result and may
allow directed STI treatment within a single visit. Such a rapid test
could effectively curtail STI transmission especially in those
vulnerable populations mentioned above.
A point-of-care test (POCT) for STI(s), also called a rapid, ‘‘bed-
side’’, ‘‘decentralized’’, or ‘‘near-patient’’ test offering immediate
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Sexually Transmitted Diseases Diagnostics Initiative (WHO
SDI). This initiative has identified benchmark criteria for an STI
POCT as being: Affordable, Sensitive, Specific, User-friendly,
Rapid and robust, Equipment-free and Deliverable to end-users
(ASSURED) [13,14]. Such assays have the ability to address some
of the STI control needs [15], especially the advantage of patients’
receiving diagnosis and treatment in a single visit in both STD
clinic or non-STD clinic settings (e.g. emergency department or
outreach mobile van). Currently available STI POCTs in clinics in
U.S. include non-pathogen specific tests such as urine dipstick and
Gram stain, to more pathogen specific tests such as wet mount test
for vaginitis, rapid plasma reagin (RPR) and darkfield examination
for syphilis, and rapid HIV test, which differs substantially from
other tests due to significance of its result. However, needs
assessment from STI experts and end users about currently
available STI POCTs and future new development has not been
conducted since WHO SDI was formed over 15 years ago [6].
Our goal was to explore the perceptions of the ideal types and
characteristics for STI POCTs for use in clinics and other care
settings through focus group discussions conducted with clinicians,
opinion leaders, and public health professionals.
Materials and Methods
Ethics Statement
This study protocol was approved by Institutional Review
Boards (IRBs) of The Johns Hopkins University School of
Medicine and Cincinnati Children’s Hospital Medical Center.
Verbal informed consent was obtained from all participants
involved in our study.
Focus Group Discussions
A total of eight focus group discussions were conducted between
March 2008 and April 2009. The first focus group, an opinion
leader group comprised of 6 directors of U.S. STD ‘‘Model
Clinics’’ identified by the Centers for Disease Control and
Prevention (CDC), was conducted during the National CDC
STD Prevention Conference in Chicago, Illinois. For the second
focus group discussion, we invited 8 U.S., U.K., and Canadian
STI experts who were attending the British Association of Sexual
Health and HIV (BASHH)-American Sexually Transmitted
Diseases Association (ASTDA) joint meeting in Brooklyn, New
York. For the first and second focus group discussions, an email
was sent to invite each participant. The remainder of focus group
discussions included clinicians from one public STD clinic; one
federally qualified health center; a U.S. community-based
organization funded under the Health Center Consolidation Act
which provides comprehensive primary care and preventive care;
one public adolescent and young adult clinic; one academic
hospital-affiliated adolescent clinic in Baltimore, Maryland; and
one group of community pediatricians and one academic hospital-
affiliated adolescent clinic in Cincinnati, Ohio. We recruited for
focus group members from state medical societies, community
clinical sites, medical teaching institutions, hospitals and other
venues using advertising and personal contact.
Participants
In total, 76 STI professionals, including 43 physicians, 20
nurse practitioners/physician assistants/registered nurses, 6 STD
clinic directors, 2 public health directors, 1 public health
laboratory director, 3 laboratory technicians, and 1 epidemiol-
ogist participated.
Focus Group Discussion Topics
Trained structured-group discussion facilitators introduced the
purpose of the project and briefly outlined the definition of a
POCT. The topics explored were: (1) currently available POCTs,
(2) perceived barriers to using POCTs in the participant’s practice
setting, (3) priority setting for the development of new POCT for
STIs, (4) envisioned characteristics of an ideal POCT, and (5)
acceptable levels of sensitivity, specificity and predictive values. In
order to ensure that all participants in the focus groups understood
the meaning of sensitivity, specificity, and predictive values, the
facilitator defined what these terms meant before participants were
asked the question regarding desirable sensitivity, specificity, and
predictable values.
Data Management and Data Analysis
Each focus group discussion session, which included responses
to the focus group facilitator and interaction between participants,
was recorded and transcribed verbatim in Microsoft Word
[16,17,18]. Each verbatim transcription served as primary text
document. Within each primary document, specific quotations
were selected and codes were assigned to a word or phrase.
Interview transcripts were read repeatedly and were systematically
coded multiple times by the investigator (Y-H H and MB) to
increase precision which was facilitated by using Atlas.ti software
(version 6, Atlas.ti GmbH, Berlin, Germany). Consistency of
coding was checked and no discrepant codes were identified. A
qualitative content analysis [19] was performed to examine
frequencies/patterns of recurring codes for potential conceptual
categories in each primary document and all verbatim transcripts.
Codes were then regrouped and indexed in order to identify
salient themes on STI POCT by using Atlas.ti software. Recurring
themes in relation to this topic were checked independently by a
second reviewer (MB) and were compared and tested by re-
reading transcripts and fine-tuning interpretations.
Results
Commonly used and reported POCTs for STIs
The most common currently used POCT for STIs reported
from participants was the wet mount test, i.e. saline and potassium
hydroxide (KOH) slide preparation of vaginal fluid for Trichomonas
vaginalis, candidiasis and bacterial vaginosis detection. Rapid HIV
test, urine dipstick, Gram stain, rapid syphilis test, i.e. RPR and
darkfield, were also commonly available and used in the
participants’ clinics. Only two participants from a focus group
conducted in Cincinnati stated that a rapid T. vaginalis test was
available in their clinics. One participant from the United
Kingdom reported a rapid syphilis test (DetermineH Syphilis TP)
available in his clinic.
Perceived Barriers in use of currently available POCTs
Participants identified barriers to use of currently available
POCTs for STIs in three main areas: (1) characteristics of the test,
(2) issues related to operations of clinic or hospital and/or
laboratory, and (3) issues related to patients. Some barriers
mentioned intertwined at least two of these three areas. Some
specific quotations from participants are presented in Table 1.
All focus groups concurred that the complexity of the test, such
as the number and timed steps, was the major barrier for use of
some currently available POCT for STIs. The complexity of the
test was frequently described as too labor intensive with multiple-
step procedures, time-driven steps, laboratory equipment usage,
and difficulty in reading and interpreting the test results. Several
respondents indicated that a POCT was supposed to be ‘‘rapid’’
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processes. In many cases, the laboratory-driven processes were
required by the hospital administration regulations, even for the
Clinical Laboratory Improvement Amendments (CLIA)-waived
POCTs, which are defined by the Food and Drug Administration
(FDA) as simple laboratory examinations and procedures that are
cleared by FDA for home use; employ methodologies that are so
simple and accurate as to render the likelihood of erroneous results
negligible; or pose no reasonable risk of harm to the patient if the
test is performed incorrectly [20]. Some participants indicated that
they believed the validity of some POCTs was questionable or the
test was not reliable, so they hesitated to use them.
Another main consensus identified by participants from all but
one (public adolescent and young adult clinic) focus group was the
interruption of clinic workflow. Due to the time for completion of
some POCT, medical providers in a clinic setting are often
required to give test results to a patient while another patient is
waiting to be seen. A couple of participants suggested that some
clinicians were not emotionally ready to give a positive/reactive
POCT result to patients in such a limited period of time, especially
for those tests offered as part of a screening panel, such as a
positive HIV test.
Finally, participants also suggested that some of the barriers
came from the patients. Resistance to the use of POCTs from
patients might be caused by the perceived invasiveness of sample
collection procedures or wait time. Participants also perceived that
some patients might not want to hear (or were not ready for) the
immediate result of a POCT that was not primarily for the
purpose of their visit that day, i.e. a screening POCT for HIV.
Priority for Development of New POCT for STIs
Chlamydia trachomatis was ranked as the top priority for
development of new POCT for STIs in 7 of 8 focus groups.
The one group which did not choose chlamydia as the top priority
did not name any particular microorganism or disease. Four of the
groups named herpes simplex virus as a second priority, two
groups identified T. vaginalis, and one group selected Neisseria
gonorrhoeae. Other STIs mentioned in the discussions included:
syphilis, HIV (for the detection of early seroconversion),
‘‘gardnerella’’ (bacterial vaginosis), yeast, and hepatitis B and C
viruses. One participant stated ‘‘we want it all’’ and expressed a
need for a multiplex platform to identify several agents. Another
participant expressed that a new POCT should detect agents of
common syndromes, e.g. non-gonococcal urethritis. One partic-
ipant stated that the priority should focus on a test that could rule
out several organisms.
Characteristics of an Ideal POCT for STIs
The groups unanimously cited the over-the-counter home-use
pregnancy test as the prototype model for an ideal POCT for
STIs. Most focus group members stated they wanted a POCT ‘‘just
like a pregnancy test’’, both characteristically and physically.
Table 1. Some quotes on point-of-care tests (POCTs) for sexually transmitted infections (STIs) from the participants of structured
discussion sessions.
Perceived Barriers in use of currently available POCTs
Characteristics of the test
‘‘multistep long tests aren’t going to fly in our clinic. I mean, we’ve done studies with them to look at their response characteristic that would require hiring new staff.’’
‘‘not quite rapid’’
‘‘Difficulty of reading the results – faint, faint lines that you’re not sure whether it’s positive or negative or what to do about it.’’
Related to clinic operation
‘‘…the provider being interrupted while working with another patient just to give results…’’
‘‘the lab services are now being covered by the hospital labs. So, that’s basically been a barrier to introduce new testing because they insist on higher levels of
competency, competency training, foundation and each individual test has to be validated.’’
Related to patients
‘‘trying to see the next patient and get back to the first patient, when the first patient is waiting much too long for something that’s supposed to be rapid.’’
‘‘Some patients don’t wanna get stuck for blood, they don’t wanna be swabbed – so lack of patient participation.’’
Characteristics of an ideal POCT for STIs
‘‘like a pregnancy test’’
‘‘something simple to use maybe one part as opposed to five different things’’
‘‘I don’t care what it looks like as long as it works.’’
‘‘the quicker, the better’’
‘‘We wish it could be 5 minutes but that would be impossible.’’
‘‘…a CLIA-waived test would be helpful because in that sense someone else could potentially do it, even the clinician.’’
‘‘The test should not require a great amount of technical ability to allow clinicians to easily run the test. Patient should be able to do the test without assistance and
techs, too.’’
‘‘have a yes or no, plus or minus when the test is done.’’
‘‘Something that stays flat would be nice. Because I am always worried with the oral test, I’m afraid I will knock it over.’’
‘‘Cheap enough that we afford it’’
Sensitivity, Specificity and Predictive Values
‘‘I would say close to a 100% as you can make it.’’
‘‘It could be on the same level of a screening test that usually we get.’’
doi:10.1371/journal.pone.0014144.t001
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important characteristics that an ideal POCT should possess. This
test should be ‘‘simple to use’’ and ‘‘user-friendly’’ – i.e. should not
require a great amount of technical ability to allow a physician,
other clinic staff member or even the patient to run the test
without any assistance. The test should be a CLIA-waived test. In
addition, the ‘‘test result should be easily read and interpreted with a yes or
no when the test is done’’. Accuracy of the POCT was also important
for the participants. A POCT with high sensitivity and specificity
was desired.
The ideal STI POCT should have a rapid turn-around time.
Most participants preferred to have a much shorter turn-around
time; as one participant stated ‘‘the quicker, the better’’ or another
stated ‘‘15 seconds’’. Participants recognized such a short time
frame is unlikely, as one participant described ‘‘We wish it could be
5 minutes but that would be impossible.’’ The majority’s consensus was
that 20 minutes is acceptable as the limit of required time but that
5 minutes or less was preferred. One participant stated ‘‘a 30-
minute POCT is alright if it can detect chlamydia, gonorrhea, trichomonas,
and HIV simultaneously’’.
Participants also preferred the ideal POCT to be compact,
durable, and sturdy, the same physical characteristics that the
pregnancy test possesses. They specifically stated that the ideal test
should not be easily knocked over in a busy clinic setting. Finally,
they wished the sample collection to be non-invasive, in order to
increase acceptability of the test, especially from the perspective of
the patients. Some specific quotations from participants were
presented in Table 1.
Sensitivity, Specificity and Predictive Values
Most participants stated the sensitivity of an ideal STI POCT
should be 90% or above, preferably the high 90s, close to 100%,
and one participant preferred both sensitivity and specificity as
100%. A few participants would accept a sensitivity of at least
80%. Regarding specificity, the majority wanted it to be similar to
the sensitivity, preferably high 90s, close to 100%. Some said the
specificity could be traded off a little as compared to the sensitivity.
One said that specificity can be low, ‘‘around 75–80%’’. Some
participants who did not provide numbers for the sensitivity and
specificity stated they would like to have the sensitivity and
specificity as high as current tests or as good as nucleic acid
amplification tests. Some participants stated that understanding
the disease prevalence in the population in which the test would be
employed is important, and positive and negative predictive values
of the POCT were more important for clinicians than the
sensitivity and specificity. A few participants mentioned the
specific values of predictive values that they would like to see in
an ideal STI POCT. One stated 97% and another stated 80% for
a positive predictive value.
Discussion
To our knowledge, this is the first large-scale in-depth qualitative
study illustrating what the clinicians perceive as necessary to make a
POCT for STIs practical. Our focus group discussions first
documented the barriers encountered or perceived barriers in
currently available POCT for STIs, including test-related, clinic
operation-related, and patient-related aspects. Discussion session
participants further identified the direction for the development of
new STI POCTs. They chose chlamydia as the first pathogen for
prioritizing the development of a new POCT, and they listed
characteristics of an ideal POC diagnostic which would overcome
the barriers they identified accordingly. Most of these characteristics
have been identified by Mabey and his colleagues 15 years ago [6],
indicating there has been little progress on meeting clinicians’ needs
on the subject of POCT for STIs.
It is not surprising that chlamydia was the preferred choice for a
new STI POCT from the 8 structured group discussions. High
prevalence and incidence [1], unavailability of a reliable POCT
[13,21], and relative difficulty to diagnose are likely the main
reasons that participants overwhelmingly favored chlamydia over
other STI pathogens for a new POCT. Some of reasons mentioned
above are also likely to explain why herpes simplex virus and T.
vaginalis were the second and third preferred organisms on the ‘‘wish
list’’ for the development of a new POCT. Developing POCTs
which can detect multiple pathogens or specific disease condition,
e.g. early seroconversion of HIV infection, common syndromes,
were mentioned and discussed; however, it appeared they were not
the top priority at the current time.
Overwhelmingly, the over-the-counter (OTC) pregnancy test is
viewed by all participants as the perfect prototype for an ideal STI
POCT, even though the accuracy has been questioned and a faint-
colored line has always been an issue for result interpretation [22].
OTC pregnancy test’s favorable test performance, operation, and
physical characteristics were the same characteristics that the
participants would envision an ideal STI POCT to possess. With
physical and performance characteristics similar to a pregnancy
test, which is well acceptable from both clinicians and patients, a
new POCT would be in a good position to be widely acceptable
and useful in the clinics.
Complexity of the test, including multiple-step procedures,
time-step driven processes, laboratory-driven issues, and difficulty
in reading and interpreting the test results, was a major barrier
identified by participants during the discussion sessions. Partici-
pants indicated that fewer steps, minimal time-measuring steps, a
simple dichotomous yes/no or +/2 result indicator would make
the POCT simple to use and user-friendly in their busy clinic
environment. Uniformly, all claimed a CLIA-waived test per-
formed while the patient was in the clinic would be ideal. Thus,
this characteristic could reduce the overall turn-around time. In
addition, this would allow medical providers to perform testing on
patients, or even patients to perform self-testing, initiating a
pathway for home testing POCTs that could be used as OTC tests
for STIs.
Operation-related barriers, including interruption of clinic work
flow and administration regulations, were another main area of
perceived barriers. Most of the time, these barriers resulted from
the complexity of the test previously described above. All
contribute to the interruption of clinic or office work flow.
Another important factor was the turn-around time. If turn-
around time is longer than the average time allocated for clinician-
patient interaction, patients will have to wait, and clinicians will
have to interrupt their workup for a new patient in order to give
the result to the patient whom they saw earlier. Otherwise, patients
have to wait until clinicians have time to disclose the result; which
brings up another important barrier from the patient’s perspective,
and that is a potentially long wait time for the POCT result. Thus,
if a new POCT can reduce the complexity of the diagnostic as well
as the overall turn-around time, ensuring a feasible and efficient
clinic workflow, acceptance of the new test may be probable. Some
institutions or clinics may follow a conservative path or may take a
longer time when incorporating a new U.S. FDA-approved
diagnostic, in part because of concern for potential litigation
associated with the use of a new test in their clinical practice.
Addressing these issues is beyond the scope of this current project.
Finally, some patient-related barriers affecting patient accept-
ability to the test were perceived by our clinician participants.
These included long wait time, invasiveness of sample collection
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necessarily part of their reason for visit. A new POCT with rapid
turn-around time, using non-invasive specimen types such as
urine, vaginal swab, or saliva specimens, would minimize most of
the barriers in this area. Therefore, to better understand these
barriers and the wish list for an ideal POCT, another study has
been initiated using the same qualitative approach in patients with
or at risk for STIs.
In general, little disagreement was observed during each focus
group discussion session. However, some variability was found
between sessions, which could result from some specific exposures
or experiences that the discussants have had. For example, the
rapid syphilis test was only indicated by a professional from United
Kingdom and the rapid T. vaginalis test was mentioned in two
sessions held in Cincinnati. These two sessions also ranked T.
vaginalis as second preferred organisms for the development of a new
POCT.
The main limitation of this study is that our eight focus group
discussions might not be representative of opinions of all STI
professionals. However, we have tried to include STI experts,
directors of 6 U.S. model STD clinics, and clinicians who use and
would use new POCTs for STIs from a wide range of clinics where
their patients are at high risk for STIs. We feel that, in this
exploratory study aiming to discover themes and patterns, and to
build initial models of how the ideal POCT should work, our
findings provide imperative preliminary evidence of barriers to use
of currently available POCTs, priority for development of new
POCT, and characteristics of an ideal STI POCT. These results
have been used to design a series of survey questionnaires for the
industry representatives who are interested in development of new
STI POCTs and the clinicians who would use new test.
In conclusion, our study provided substantial information in the
formative stage of assessment identifying the need for and
perception of qualities imperative for an ideal new STI POCT.
Our focus group discussion sessions concluded that chlamydia was
considered as the top priority pathogen for development and that
ease of use, rapid turnaround and high accuracy were considered
as essential characteristics of an ideal POCT. Our findings serve as
important guidance for the development of a survey instrument for
the end-users and for the direction of the development of a new
and ideal STI POCT for use by practitioners working in public
health, academia, and industry.
Acknowledgments
The results of this study, in part, were presented at the 18th International
Society for Sexually Transmitted Diseases Research Meeting in June 2009
in London, United Kingdom.
Author Contributions
Conceived and designed the experiments: MTH MJG JH AMR CAG.
Performed the experiments: MTH MB. Analyzed the data: YHH. Wrote
the paper: YHH MTH AMR CAG.
References
1. Centers for Disease Control and Prevention (2009) Sexually Transmitted
Diseases in the United States, 2008 - National Surveillance Data for Chlamydia,
Gonorrhea, and Syphilis. Accessed on January 13, 2010. http://www.cdc.gov/
std/stats08/trends.htm.
2. Chesson H, Blandford J, Gift T, Tao G, Irwin K (2004) The estimated direct
medical cost of sexually transmitted diseases among American youth, 2000.
Perspect Sex Reprod Health 36: 11–19.
3. Institute of Medicine (1997) The Hidden Epidemic - Confronting Sexually
Transmitted Diseases.; Eng T, Butler W, eds. Washington, D.C.: National
Academy Press.
4. Schwebke J, Sadler R, Sutton J, Hook Er (1997) Positive screening tests for
gonorrhea and chlamydial infection fail to lead consistently to treatment of
patients attending a sexually transmitted disease clinic. Sex Transm Dis 24:
181–184.
5. Swain G, McDonald R, Pfister J, Gradus M, Sedmak G, et al. (2004) Decision
analysis: point-of-care Chlamydia testing vs. laboratory-based methods. Clin
Med Res 2: 29–35.
6. Mabey D, Peeling R, Perkins M (2001) Rapid and simple point of care
diagnostics for STIs. Sex Transm Infect 77: 397–398.
7. Greer L, Wendel GJ (2008) Rapid diagnostic methods in sexually transmitted
infections. Infect Dis Clin North Am 22: 601–617.
8. Cunningham S, Tschann J, Gurvey J, Fortenberry J, Ellen J (2002) Attitudes
about sexual disclosure and perceptions of stigma and shame. Sex Transm Infect
78: 334–338.
9. Lichtenstein B (2003) Stigma as a barrier to treatment of sexually transmitted
infection in the American deep south: issues of race, gender and poverty. Soc Sci
Med 57: 2435–2445.
10. Rusch M, Shoveller J, Burgess S, Stancer K, Patrick D, et al. (2008) Association
of sexually transmitted disease-related stigma with sexual health care among
women attending a community clinic program. Sex Transm Dis 35: 553–557.
11. Parrish D, Kent C (2008) Access to care issues for African American
communities: implications for STD disparities. Sex Transm Dis 35: S19–22.
12. Kane B (1999) Point-of-care testing: instant gratification? Ann Intern Med 130:
870–872.
13. Peeling R, Holmes K, Mabey D, Ronald A (2006) Rapid tests for sexually
transmitted infections (STIs): the way forward. Sex Transm Infect 82: v1–6.
14. WHO/OMS (2001) World Health Organization Sexually Transmitted Diseases
Diagnostics Initiative. Accessed on January 13, 2010. http://www.who.int/
std_diagnostics/about_SDI/priorities.htm.
15. Ward P (2006) Near-patient testing will improve the control of sexually
transmitted infections: the arguments in favour. Sex Transm Infect 82: 506–508.
16. Morgan D (1998) The Focus Group Guidebook. Thousand Oaks, CA: Sage.
17. Kitzinger J (1995) Qualitative research. Introducing focus groups. BMJ 311:
299–302.
18. Powell R, Single H (1996) Focus groups. Int J Qual Health Care 8: 499–504.
19. Hsieh H, Shannon S (2005) Three approaches to qualitative content analysis.
Qual Health Res 15: 1277–1288.
20. U.S. Food and Drug Administration (2009) CLIA Waivers. Accessed on September
15, 2010. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/
IVDRegulatoryAssistance/ucm124202.htm.
21. Sabido ´ M, Herna ´ndez G, Gonza ´lez V, Valle `s X, Montoliu A, et al. (2009)
Clinic-based evaluation of a rapid point-of-care test for detection of Chlamydia
trachomatis in specimens from sex workers in Escuintla, Guatemala. J Clin
Microbiol 47: 475–476.
22. Cole L, Khanlian S, Sutton J, Davies S, Rayburn W (2004) Accuracy of home
pregnancy tests at the time of missed menses. Am J Obstet Gynecol 190:
100–105.
Perception of Ideal STI POCTs
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e14144